Antilymphocyte Immune Globulin

Antilymphocyte Immune Globulin may be added in immunosuppressant regimens in organ transplantation patient to treat acute rejection episode, Antilymphocyte Immune Globulin is also used in the treatment of aplastic anemia in patients unsuitable for bone marrow transplantation.

Antilymphocyte Immune Globulin is primarily indicated in conditions like Aplastic anemia, Bone marrow depletion of T-cells, Rejection crises of transplanted organs.

Antilymphocyte Immune Globulin is contraindicated in conditions like Allergy, Thrombocytopenia, Seizures, Parasite infection.

The severe or irreversible adverse effects of Antilymphocyte Immune Globulin, which give rise to further complications include Tachycardia, Hypotension, Febrile reactions. Antilymphocyte Immune Globulin produces potentially life-threatening effects which include Anaphylactoid reactions, Thrombocytopenia, Serum sickness. which are responsible for the discontinuation of Antilymphocyte Immune Globulin therapy. The symptomatic adverse reactions produced by Antilymphocyte Immune Globulin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Pruritus, Local thrombophlebitis, Erythema.

(See Boxed Warning.) Monitor patients for lymphoproliferative disorders and/or opportunistic infections; risk is increased with immunosuppressive therapy. Neither complication occurred more often with basiliximab than with placebo in clinical trials. Severe, acute (onset within 24 hours) hypersensitivity reactions, including anaphylaxis, have occurred after initial basiliximab exposure and subsequent reexposure. Drugs to treat severe hypersensitivity reactions, including anaphylaxis, should be immediately available. In patients who have previously received the drug, a subsequent course of therapy with basiliximab should be given with extreme caution; risks of subsequent administration not known. If hypersensitivity reaction occurs, immediately and permanently discontinue basiliximab and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, maintenance of an adequate airway and oxygen). Patients who have a severe hypersensitivity reaction to basiliximab should not receive the drug again. Not known whether the immune response to vaccines, infection, and other antigens is impaired during therapy or will remain impaired following therapy. An anti-idiotype antibody response has been detected in renal-transplant patients treated with basiliximab. No deleterious clinical effect and no evidence of faster basiliximab clearance or shorter duration of basiliximab saturation of IL-2Rα detected in the presence of anti-idiotype antibody. Clinical data suggest that subsequent use of muromonab-CD3 or other murine anti-lymphocytic antibody preparations is not precluded. Category B. Manufacturer recommends use of effective contraception before, during, and for 4 months following basiliximab use in women of childbearing potential. Not known whether basiliximab is distributed into milk. Discontinue nursing or the drug. Use in children 1–16 years of age for prevention of renal allograft rejection is supported by limited data from a pediatric safety and pharmacokinetic study. Limited data in patients ≥65 years of age suggest an adverse effect profile similar to that in younger adults; use immunosuppressive drugs with caution in such patients.

(See Boxed Warning.) Monitor patients for lymphoproliferative disorders and/or opportunistic infections; risk is increased with immunosuppressive therapy. Neither complication occurred more often with basiliximab than with placebo in clinical trials. Severe, acute (onset within 24 hours) hypersensitivity reactions, including anaphylaxis, have occurred after initial basiliximab exposure and subsequent reexposure. Drugs to treat severe hypersensitivity reactions, including anaphylaxis, should be immediately available. In patients who have previously received the drug, a subsequent course of therapy with basiliximab should be given with extreme caution; risks of subsequent administration not known. If hypersensitivity reaction occurs, immediately and permanently discontinue basiliximab and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, maintenance of an adequate airway and oxygen). Patients who have a severe hypersensitivity reaction to basiliximab should not receive the drug again. Not known whether the immune response to vaccines, infection, and other antigens is impaired during therapy or will remain impaired following therapy. An anti-idiotype antibody response has been detected in renal-transplant patients treated with basiliximab. No deleterious clinical effect and no evidence of faster basiliximab clearance or shorter duration of basiliximab saturation of IL-2Rα detected in the presence of anti-idiotype antibody. Clinical data suggest that subsequent use of muromonab-CD3 or other murine anti-lymphocytic antibody preparations is not precluded. Category B. Manufacturer recommends use of effective contraception before, during, and for 4 months following basiliximab use in women of childbearing potential. Not known whether basiliximab is distributed into milk. Discontinue nursing or the drug. Use in children 1–16 years of age for prevention of renal allograft rejection is supported by limited data from a pediatric safety and pharmacokinetic study. Limited data in patients ≥65 years of age suggest an adverse effect profile similar to that in younger adults; use immunosuppressive drugs with caution in such patients.

0.041 to 0.125 mg/kg.min (0.083 (0.083)) As recommended. IV Inf — For 4 Hours

No child dosage information is recorded for this medicine yet.

Not used in this age group ( ) —

No data regarding the interactions of Antilymphocyte Immune Globulin was found.

Ampule Store in refrigerator. Do not Freeze. Inj (reconstituted soln) Store in refrigerator. Use within 24 hrs if kept at room temperature.